Takeda gets expanded EC approval for lymphoma drug Adcetris

This article was originally published here

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE)

The post Takeda gets expanded EC approval for lymphoma drug Adcetris appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply